Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.An antibiotic can help some sufferers of irritable bowel syndrome, marking the first potential drug treatment for the disease which affects 30 million people in the United States, said a study released Wednesday.
The ailment causes bloating, abdominal pain, watery stool or constipation, and the findings in the New England Journal of Medicine appear to confirm studies in the past decade that suggest it is caused by bacteria in the gut.
"These results support the idea that intestinal microbiota or gut bacteria may be an underlying cause of IBS, and altering gut bacteria by treatment with rifaximin appears to be an effective way of providing relief to those who suffer from IBS symptoms," said co-author Yehuda Ringel.
The US Food and Drug Administration has already approved rifaximin, marketed as Xifaxan by Salix Pharmaceuticals, for treatment of travelers' diarrhea.
According to Mark Pimentel, who headed clinical trials at Cedars-Sinai, some subjects in the study experienced pain relief for weeks after they stopped taking the antibiotic.
"With this antibiotic treatment, the patients feel better, and they continue to feel better after stopping the drug. This means that we did something to strike at the cause of the disease," Pimentel said.
"For years, the treatment options for IBS patients have been extremely limited," he added. "IBS often does not respond well to treatments currently available, such as dietary changes and fiber supplements alone."
The journal noted that Pimentel "discovered the use of rifaximin for IBS," and he is "a consultant to Salix, Inc, and serves on its scientific advisory board."
The drug maker provided funding for the study, hosted at five US medical facilities, which involved more than 600 IBS sufferers with mild to moderate diarrhea and bloating.
The subjects were "randomly assigned to take a 550 milligram dose of rifaximin or placebo three times daily for two weeks. Study participants were then followed for 10 weeks more," it said.
Forty percent of patients felt relief from symptoms after taking the antibiotic for two weeks.
In comparison, about 30 percent of those taking a placebo reported similar results.
"Patients reported relief from bloating, less abdominal pain and improved stool consistency for up to 10 weeks," the study said.
js/ksh/sg
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments